{"id":"atx101","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting Nav1.5, ATX101 is thought to reduce the excitability of cardiac myocytes, thereby preventing the initiation and maintenance of atrial fibrillation. This mechanism of action is specific to the treatment of atrial fibrillation for stroke prevention.","oneSentence":"ATX101 is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.5.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:29:39.398Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT07237425","phase":"PHASE1","title":"Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma","status":"RECRUITING","sponsor":"Glonova Pharma Co., Ltd","startDate":"2025-11-14","conditions":"Lipoma, Submental Fullness","enrollment":56},{"nctId":"NCT07107802","phase":"PHASE1","title":"Phase 1 Single Ascending Dose Study With ATX101","status":"COMPLETED","sponsor":"Aurobac Therapeutics SAS","startDate":"2025-07-19","conditions":"Healthy Participants","enrollment":24},{"nctId":"NCT06799845","phase":"PHASE2","title":"Study Assessing Pain Relief After Replacement of the Knee","status":"COMPLETED","sponsor":"Allay Therapeutics, Inc.","startDate":"2025-02-03","conditions":"Total Knee Arthroplasty (Postoperative Pain)","enrollment":226},{"nctId":"NCT05260008","phase":"PHASE2","title":"Study Assessing Pain Relief After Replacement of the Knee","status":"TERMINATED","sponsor":"Allay Therapeutics, Inc.","startDate":"2022-06-07","conditions":"Acute Postoperative Pain","enrollment":112},{"nctId":"NCT03284034","phase":"NA","title":"Cryolipolysis Versus ATX-101 (Deoxycholic Acid) for Upper Back Fat","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2017-11-27","conditions":"Upper Back Fat","enrollment":8},{"nctId":"NCT04814875","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy","status":"TERMINATED","sponsor":"THERAPIM PTY LTD","startDate":"2021-09-01","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma","enrollment":16},{"nctId":"NCT05116683","phase":"PHASE2","title":"ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma","status":"TERMINATED","sponsor":"Benjamin Izar","startDate":"2022-01-11","conditions":"Leiomyosarcoma, Liposarcoma","enrollment":4},{"nctId":"NCT02035267","phase":"PHASE3","title":"Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2014-01","conditions":"Moderate to Severe Convexity of Submental Fat, Safety, Efficacy","enrollment":93},{"nctId":"NCT02163902","phase":"PHASE3","title":"Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2013-12","conditions":"Submental Fat, Healthy","enrollment":224},{"nctId":"NCT02123134","phase":"PHASE3","title":"Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2014-04","conditions":"Moderate to Severe Convexity of Submental Fat, Safety, Efficacy","enrollment":55},{"nctId":"NCT02159729","phase":"PHASE2","title":"Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2009-02","conditions":"Submental Fat, Healthy","enrollment":205},{"nctId":"NCT02438813","phase":"","title":"Condition of Submental Fullness and Treatment Outcomes Registry","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2015-05-11","conditions":"Submental Fullness","enrollment":1029},{"nctId":"NCT03682471","phase":"","title":"Long-term 24-month Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 (Sodium Deoxycholate Injection)","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-02-14","conditions":"Subcutaneous Fat","enrollment":201},{"nctId":"NCT01462786","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2011-10","conditions":"Healthy","enrollment":5},{"nctId":"NCT00608842","phase":"PHASE2","title":"Phase 2 Study for the Treatment of Superficial Lipomas","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2007-11","conditions":"Lipoma","enrollment":62},{"nctId":"NCT01426373","phase":"PHASE3","title":"Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2011-08","conditions":"Moderate or Severe Submental Fullness","enrollment":165},{"nctId":"NCT00422188","phase":"PHASE1","title":"Deoxycholic Acid Injection for the Treatment of Superficial Lipomas","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2007-01","conditions":"Lipoma","enrollment":16},{"nctId":"NCT02007434","phase":"PHASE3","title":"Patient Experience Study of Deoxycholic Acid Injection","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2013-12","conditions":"Moderate or Severe Submental Fullness","enrollment":84},{"nctId":"NCT00618722","phase":"PHASE1, PHASE2","title":"Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2007-08","conditions":"Moderate or Severe Submental Fullness","enrollment":85},{"nctId":"NCT01305577","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2010-12","conditions":"Moderate or Severe Submental Fullness","enrollment":363},{"nctId":"NCT00618618","phase":"PHASE2","title":"Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2008-04","conditions":"Moderate or Severe Submental Fullness","enrollment":73},{"nctId":"NCT01542034","phase":"PHASE3","title":"Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2012-02","conditions":"Moderate or Severe Submental Fullness","enrollment":506},{"nctId":"NCT01546142","phase":"PHASE3","title":"Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2012-03","conditions":"Moderate or Severe Submental Fullness","enrollment":516},{"nctId":"NCT01032889","phase":"PHASE2","title":"Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2009-12","conditions":"Moderate or Severe Submental Fullness","enrollment":129},{"nctId":"NCT01294644","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2011-01","conditions":"Moderate or Severe Submental Fullness","enrollment":360},{"nctId":"NCT00618709","phase":"PHASE1","title":"Dose-Escalation Safety and Pharmacokinetic Study of ATX-101","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2008-01","conditions":"Healthy","enrollment":24},{"nctId":"NCT01706679","phase":"PHASE1","title":"Evaluation of the Effect of ATX-101 on QT/QTc Intervals","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2012-10","conditions":"Healthy","enrollment":218},{"nctId":"NCT01632917","phase":"PHASE1","title":"Open-Label Pharmacokinetic Study of Final Formulations of ATX-101","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2012-06","conditions":"Healthy","enrollment":24},{"nctId":"NCT01320761","phase":"PHASE1","title":"A Study to Assess Injection Comfort of Two Formulations of ATX-101","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"","conditions":"Healthy","enrollment":24},{"nctId":"NCT01319916","phase":"PHASE1","title":"Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat Tissue","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2010-12","conditions":"Healthy","enrollment":10},{"nctId":"NCT00835952","phase":"PHASE1","title":"ATX-101 Abdominoplasty","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2008-11","conditions":"Characteristics of Subcutaneous Fat","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":79,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ATX101","genericName":"ATX101","companyName":"Aurobac Therapeutics SAS","companyId":"aurobac-therapeutics-sas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ATX101 is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.5. Used for Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}